Myasthenia gravis

This study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participan…

This study tests whether adding empasiprubart to the existing drug efgartigimod can improve symptoms and daily function in people with generalized myasthenia gravis who still have symptoms on efgartigimod alone. About 70 participants will receive both drugs intravenously. The mai…

This study is testing two drugs, efgartigimod and empasiprubart, given by IV, to see if they are safe and work well for people with myasthenia gravis (MG). The goal is to reduce side effects and improve quality of life. About 70 adults with MG are being recruited.

This phase 3 trial is testing a new oral form of cladribine, a drug that calms the immune system, in 264 adults with generalized myasthenia gravis. Participants receive either low-dose cladribine, high-dose cladribine, or a placebo in two courses four weeks apart. The main goal i…

This observational study follows 50 adults with generalized myasthenia gravis who are new to complement inhibitors and are receiving ravulizumab (Ultomiris) in Poland. Researchers will track changes in daily living activities and other symptoms over time. The goal is to see how w…

This study tests a drug called efgartigimod in 12 children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and see if it is safe. Participants receive injections and are monitored for up to 14 weeks.

This study tests an experimental drug called povetacicept in adults with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely reduces harmful immune proteins. About 30 participants will receive either the drug or a placebo,…

This study tests a drug called ravulizumab in 20 Chinese adults with generalized myasthenia gravis, a condition that causes severe muscle weakness. The drug is given through a vein and works by blocking a part of the immune system to reduce symptoms. Researchers will measure how …

This study tests an investigational drug called rozanolixizumab against a placebo in 120 adults with ocular myasthenia gravis, a condition causing eye muscle weakness like droopy eyelids or double vision. Participants receive the drug or placebo by injection, and researchers meas…

This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive the drug as a shot under the skin. The main goal is to see if it improves their ability to do daily activities after ab…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This study looks at whether efgartigimod, a drug that lowers harmful antibodies, can help elderly patients with generalized myasthenia gravis reduce their steroid use. Steroids often cause serious side effects in older adults. The study will follow 50 patients for 12 months to se…

This phase 3 trial tests whether claseprubart (DNTH103) can improve symptoms of generalized myasthenia gravis, a condition causing muscle weakness. About 195 adults with a specific antibody type are randomly assigned to receive the drug or a placebo. The main goal is to see if th…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The main goals are to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. The drug is g…

This study looks at whether giving the drug ravulizumab early, right after standard crisis treatments like plasma exchange or IVIg, can help people with severe myasthenia gravis recover faster in the ICU. About 30 adults with a specific antibody type will be followed for 6 months…

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which reduces harmf…

This study tests a daily injection called zilucoplan in 15 people hospitalized with severe myasthenia gravis (MG) flare-ups. The goal is to see if the drug can quickly improve daily living activities, like breathing and swallowing, within two weeks. Participants receive the injec…

This study tests an experimental pill called NMD670 in 84 adults with myasthenia gravis, a condition that causes muscle weakness. Participants take the pill or a placebo twice daily for 21 days. Researchers will measure changes in muscle strength and daily activities to see if th…

This study tests whether ublituximab, given as an infusion, can help adults with myasthenia gravis maintain symptom control after initial treatment with efgartigimod. Participants will receive either ublituximab or a placebo, and researchers will track how long it takes for sympt…

This study tests a new drug called B007 in 104 people with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either B007 or a placebo as a shot under the skin twice a month. The goal is to see if B007 improves daily activities, like walk…

This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…

This early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …

This phase 1 trial is testing an experimental therapy called SYS6020 for people with refractory generalized myasthenia gravis, a chronic autoimmune condition that causes severe muscle weakness. SYS6020 uses a patient's own immune cells, engineered to target BCMA, a protein involv…

This study tests a new drug, aritinercept, in 81 adults with generalized myasthenia gravis. The drug works by blocking two immune signals (BAFF and APRIL) to reduce disease activity. Researchers are checking if it is safe and if it improves daily living activities compared to a p…

This study is testing a drug called zilucoplan in children aged 2 to 17 with generalized myasthenia gravis, a disease that causes muscle weakness. The goal is to see how the drug works in the body, if it is safe, and if it helps control the disease. Only 8 children will take part…

This study tests a drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely lowers certain immune proteins (IgG) and improves daily activities. About 12 children will receiv…

This study tests an investigational drug called IMVT-1402 in 231 adults with mild to severe generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it improves daily activities and muscle strength. The goal i…

This study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard immunosuppressive drugs for generalized myasthenia gravis. About 66 adults who have not responded to at least two prior therapies will be randomly assigned to receive either …

This Phase 3 study tests whether remibrutinib can improve daily function in adults with generalized myasthenia gravis, a condition that causes muscle weakness. About 180 participants will receive either the drug or a placebo for 6 months, followed by an open-label phase where eve…

This study tests an investigational drug, nipocalimab, in adults with generalized myasthenia gravis (gMG), a condition causing muscle weakness. About 199 participants will receive either nipocalimab or a placebo to see if it improves daily activities and muscle strength. The drug…

This study tests a drug called telitacicept in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo for 24 weeks to see if it improves daily activities and muscle strength. The goal is to control the…

This study follows 100 adults in Italy with generalized myasthenia gravis who are starting efgartigimod as part of their routine care. Researchers will track changes in symptoms and daily activities over up to 23 months using patient reports and doctor assessments. The goal is to…

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This study is testing whether the drug ravulizumab can help people with generalized myasthenia gravis (gMG) safely reduce or stop taking oral steroids. About 75 adults who are already on ravulizumab and taking at least 7.5 mg of prednisone daily will follow a gradual steroid-tape…

This Phase 3 trial tests whether telitacicept can improve eye muscle symptoms in people with ocular myasthenia gravis, a condition causing droopy eyelids and double vision. About 120 participants aged 12 to 80 will receive either the drug or a placebo for 24 weeks. The study meas…

This study tests a drug called gefurulimab in 12 children aged 6 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The drug works by blocking a part of the immune system to reduce symptoms. Participants receive weekly injections, and researchers w…

This early study is testing a new drug, HN2302 (a type of in vivo CAR-T therapy), in just 6 people with refractory myasthenia gravis — a condition where standard treatments fail. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps wi…

This early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…

This study tests a drug called efgartigimod in 30 adults who were diagnosed with generalized myasthenia gravis (gMG) within the past year. The goal is to see if it can quickly reduce muscle weakness and daily-life symptoms. Participants receive weekly injections for about a year,…

This early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…

This early-phase study tests a new treatment called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis, a condition that causes muscle weakness. Anito-cel is a type of CAR T-cell therapy that targets BCMA, a protein on certain immune cells. The tr…

This study is testing a drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given through an IV and aims to lower harmful antibodies. Researchers will check how the drug moves through the body,…

This study tests a new medicine called IM-101 for adults with myasthenia gravis, a disease that causes muscle weakness. The trial has two parts: first, checking safety and dosing in people with a specific antibody type, then testing how well it works in broader groups. About 96 p…

This study tests whether the drug ravulizumab can improve daily activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR-positive). About 40 participants will receive treatment and be followed for 50 weeks. The main goal is to see if …

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This study looks at 200 adults with new-onset ocular myasthenia gravis, a condition that causes droopy eyelids and double vision. Researchers will compare different treatments, including steroids and immunosuppressants like azathioprine and tacrolimus, to see which works best and…

This study tests whether starting steroids right away, and adding rituximab if symptoms return, can prevent eye muscle weakness from spreading to other muscles in people with ocular myasthenia gravis. About 128 adults with recent diagnosis will be followed for 2 years. The goal i…

This early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with severe autoimmune diseases like multiple sclerosis, myasthenia gravis, and neuromyelitis op…

This study looks at how well a new drug called Zilucoplan works for people with myasthenia gravis, a disease that causes muscle weakness. Researchers will track 55 French patients over three months to see if the drug improves muscle strength and daily life, and check for side eff…

This early-stage trial is testing a new type of immune cell therapy called CD19-BCMA CAR-T in 9 adults with severe myasthenia gravis that hasn't improved with standard treatments. The therapy uses a patient's own modified immune cells to target and attack the faulty cells causing…

This early study tests a new treatment called GC012F, made from a patient's own immune cells (CAR-T cells), for people with refractory generalized myasthenia gravis that hasn't responded to standard therapies. Six participants will receive a single infusion of these modified cell…

This early-phase study tests a new drug called cizutamig in 44 adults with generalized myasthenia gravis, a condition causing muscle weakness. The main goal is to check safety and how the body processes the drug. Participants must have moderate symptoms and not have responded wel…

This study looks at whether light or moderate exercise is better for adults with myasthenia gravis, a condition that causes muscle weakness. Twenty participants will join a 12-week exercise program three times a week. The goal is to see which intensity is more doable and improves…

This study tests whether whole-body electrical muscle stimulation (WB-EMS) can help adults with neuromuscular diseases like ALS, SMA, and muscular dystrophy exercise safely. Because these conditions weaken the nerves that control muscles, traditional exercise is often too hard. W…

This study watches how doctors in Russia treat adults with a rare muscle-weakening disease called generalized myasthenia gravis (gMG). It does not test any new drug. Instead, it collects information from medical records and routine check-ups for about 450 people over time. The go…

This study follows 50 adults with generalized myasthenia gravis who are taking Rozanolixizumab. Researchers want to see how the drug affects symptoms like fatigue and muscle weakness from the patient's own point of view. Participants will fill out a special questionnaire over 9 m…

This pilot study explores whether continuous monitoring with wearable devices and remote neurological exams can detect worsening in people with myasthenia gravis (MG), a condition causing fluctuating muscle weakness. The goal is to see if this technology is reliable and if patien…

This study investigates whether anti-AChR antibodies, found in the spinal fluid of people with myasthenia gravis, are associated with cognitive disorders. Researchers will compare antibody levels in stored spinal fluid and a fresh blood sample from adults with myasthenia and cogn…

This registry study follows adults with myasthenia gravis (MG) over time to understand how symptoms, daily functioning, and quality of life change. Participants complete surveys about their symptoms, treatments, and challenges, and may share medical records. The goal is to gather…

This study is a pregnancy registry that gathers information from women with chronic neurological conditions like multiple sclerosis, NMOSD, and myasthenia gravis who are planning pregnancy, currently pregnant, or within one year postpartum. Participants can contribute blood, brea…

This study aims to collect saliva samples from 1,000 people with a lab-confirmed diagnosis of MuSK myasthenia gravis, a rare autoimmune condition that weakens muscles. By comparing genetic information, researchers hope to identify variations linked to the disease. The findings co…

This study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…

This study investigates why about 10-15% of people with generalized myasthenia gravis (MG) do not respond to standard treatments. Researchers will take blood samples from 40 adults with MG and from healthy controls, then expose lab-grown human neuromuscular organoids to antibodie…

This study will use smartphone recordings of speech, eye movements, and arm fatigue to measure key symptoms of myasthenia gravis, a condition that causes muscle weakness. Researchers will compare 225 participants (both with and without MG) to see if machine learning can accuratel…

This study follows 100 women with neuroimmune diseases (like multiple sclerosis or myasthenia gravis) through pregnancy and up to five years after. Researchers will track disease activity, pregnancy complications, and baby health to learn how these conditions affect fertility and…

This study looks at why people with myasthenia gravis (MG) feel short of breath, even during rest or sleep. Researchers will use breathing tests, sleep studies, and questionnaires in 50 adults with MG to uncover the causes. The goal is to find better ways to ease discomfort and p…

This study is testing a new, non-invasive brain monitor (Neurosteer) in 100 ICU patients who are on breathing machines and sedatives. The monitor is a small device placed on the forehead that measures brain activity. Researchers want to see if it can accurately track levels of se…

This study follows 75 pregnant women who have taken Ultomiris (ravulizumab) for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and baby health up to one year after birth. The goal is to gather safety information, not to test a new treatment.

This study tests whether artificial intelligence can analyze tongue images to help diagnose myasthenia gravis, a chronic muscle weakness condition. Researchers will compare tongue photos and heart rate data from 100 people with the disease and healthy volunteers. The goal is to m…

This study follows pregnant women who have taken efgartigimod for myasthenia gravis or CIDP, as well as women exposed only during breastfeeding. Researchers will monitor pregnancy outcomes and infant health, including birth defects, to better understand the drug's safety. The goa…

This study is a long-term, global registry that follows 500 people with generalized myasthenia gravis who are taking or have taken C5 inhibitor drugs like Soliris or Ultomiris. The goal is to collect real-world data on safety and how well the treatment helps with daily activities…

This study follows 680 people with generalized myasthenia gravis to see how safe efgartigimod is over the long term. Some participants take the drug, while others do not. Researchers will compare rates of serious infections and other side effects between the two groups.

This study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study is creating a registry of 800 adults with myasthenia gravis at Yale University. Participants donate blood and stool samples, which will be used for future research to better understand the disease. The goal is to collect data and samples to support many research projec…